Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the company’s shareholders approved the management proposals with a large majority (between 98.03% and 99.99%) at today’s ordinary virtual Annual General Meeting.
– All agenda items approved by a large majority
– 2025 Annual General Meeting elects Dr Karl Benedikt Biesinger and Dr Klaus Schollmeier as new members of the Supervisory Board
– Supervisory Board elects Dr Karl Benedikt Biesinger as new Chairman